The United Arab Emirates (UAE) has initiated clinical trials of Russia’s Sputnik V vaccine for Covid-19 as the number of cases surge in the country.

Sputnik V was developed by the Ministry of Health of the Russian Federation’s Gamaleya Research Institute of Epidemiology and Microbiology.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The Phase III trials, which were announced last October, will enrol up to 500 participants in the initial stage, Reuters reported.

Healthy adults of various nationalities living in Abu Dhabi, who are neither previously infected with Covid-19 nor have been part of any Covid-19 vaccination trial, will be inoculated in these trials.

The participants will receive two doses of the vaccine, which will be administered 20 days apart, at a hospital in Abu Dhabi.

They will be followed up through regular visits and teleconsultations for 180 days after the treatment.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Data from the first two phases of the trial had shown that the subjects receiving Sputnik V vaccine had a stable humoral as well as cellular immune response and no serious adverse events were noted.

Separately, the UAE is carrying out Phase III trials of a vaccine developed by China National Pharmaceutical Group (Sinopharm).

As per the UAE health ministry, the vaccine is authorised in the country and is available for free on a priority basis to more vulnerable people.

Last month, the emirate of Dubai initiated vaccinating individuals with Pfizer and BioNTech’s vaccine.
As of 5 January, 826,301 vaccines had been administered to the people.

Furthermore, the UAE intends to inoculate over 50% of the population in the first quarter of this year.

In July last year, Sinopharm initiated a Phase III clinical trial to assess its Covid-19 vaccine candidate in Abu Dhabi, UAE.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact